Nothing Special   »   [go: up one dir, main page]

ME00054B - Acetonski solvati dimetoksi docetaksela i postupci za njihovo dobijanje - Google Patents

Acetonski solvati dimetoksi docetaksela i postupci za njihovo dobijanje

Info

Publication number
ME00054B
ME00054B MEP-2008-117A MEP2008117A ME00054B ME 00054 B ME00054 B ME 00054B ME P2008117 A MEP2008117 A ME P2008117A ME 00054 B ME00054 B ME 00054B
Authority
ME
Montenegro
Prior art keywords
dimethoxy
preparation
hydroxy
acetone solvate
dimethoxy docetaxel
Prior art date
Application number
MEP-2008-117A
Other languages
English (en)
Inventor
Eric Didier
Marc Antoine Perrin
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00054(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ME00054B publication Critical patent/ME00054B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Pronalazakse odnosi na acetonske derivate dimetoksi docetakse la ili 4-acetoksi-2α­benzoiloksi-5β,20-e poksi-l-hidroksi-7β, 10β -dimetoksi-9-oksotaks- 11-en -13α -il (2R,3S)-3-terc-butoksikarbonilamin o-2-hidroksi-3-fe nilpropi onata i    na njihovodobijanje kri sta lizacijom iz hidro-acetonskog rastvora . Pronalazak se odnosi na acetonske derivate dimeto k s i doceta k s e la ili 4-acetoksi-2α­ benzoilo k si- 5 β ,20- e p o k s i-l-hidro k si-7β, 10β -dime t o k si- 9 -o k s o ta k s- 11 - e n -13α -il ( 2 R ,3S ) -3-terc-butoksikarbonilamin o - 2 - hid r o k si-3-fe nilp r o p i o na t a i     na nji h ovo d o bi j a n j e kr i sta lizaci j om iz hid r o - a cet o n skog r a stvo r a .
MEP-2008-117A 2003-09-19 2004-09-16 Acetonski solvati dimetoksi docetaksela i postupci za njihovo dobijanje ME00054B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation
PCT/FR2004/002344 WO2005028462A1 (fr) 2003-09-19 2004-09-16 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (1)

Publication Number Publication Date
ME00054B true ME00054B (me) 2011-02-10

Family

ID=34224354

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-117/08A MEP11708A (en) 2003-09-19 2004-09-16 Dimethoxy docetaxel acetone solvate et method for the preparation thereof
MEP-2008-117A ME00054B (me) 2003-09-19 2004-09-16 Acetonski solvati dimetoksi docetaksela i postupci za njihovo dobijanje

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-117/08A MEP11708A (en) 2003-09-19 2004-09-16 Dimethoxy docetaxel acetone solvate et method for the preparation thereof

Country Status (38)

Country Link
US (1) US7241907B2 (me)
EP (1) EP1667986B1 (me)
JP (1) JP5010279B2 (me)
KR (1) KR101123588B1 (me)
CN (1) CN100429207C (me)
AR (1) AR045667A1 (me)
AU (1) AU2004274212B2 (me)
BE (1) BE2013C036I2 (me)
BR (1) BRPI0414492A8 (me)
CA (1) CA2539309A1 (me)
CR (1) CR8292A (me)
CY (2) CY1114575T1 (me)
DK (1) DK1667986T3 (me)
ES (1) ES2403149T4 (me)
FR (2) FR2859996B1 (me)
HK (1) HK1093340A1 (me)
HR (1) HRP20130322T1 (me)
HU (1) HUS1300025I1 (me)
IL (1) IL174240A (me)
LU (1) LU92172I2 (me)
MA (1) MA28045A1 (me)
ME (2) MEP11708A (me)
MX (1) MXPA06002639A (me)
MY (1) MY136668A (me)
NO (2) NO335997B1 (me)
NZ (1) NZ545835A (me)
PA (1) PA8612401A1 (me)
PE (1) PE20050870A1 (me)
PL (1) PL1667986T3 (me)
PT (1) PT1667986E (me)
RS (2) RS54614B1 (me)
RU (1) RU2342373C2 (me)
SI (1) SI1667986T1 (me)
TN (1) TNSN06086A1 (me)
TW (1) TWI382022B (me)
UA (1) UA87115C2 (me)
WO (1) WO2005028462A1 (me)
ZA (1) ZA200602255B (me)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001874A4 (en) * 2006-03-21 2010-04-07 Reddys Lab Ltd Dr DOCETAXEL POLYMORPH AND CORRESPONDING METHODS
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
PE20121429A1 (es) * 2009-10-29 2012-11-06 Aventis Pharma Sa Nuevo uso antitumoral de cabazitaxel
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
ES2621800T3 (es) * 2011-04-12 2017-07-05 Teva Pharmaceuticals International Gmbh Formas de estado sólido de cabazitaxel y procesos de preparación de las mismas
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
US8722900B2 (en) 2011-10-31 2014-05-13 Scinopharm Taiwan, Ltd. Process for cabazitaxel, and intermediates thereof
CN103874692A (zh) 2011-11-01 2014-06-18 费森尤斯卡比肿瘤学有限公司 卡巴他赛的无定形形式和用于其制备的方法
WO2013080217A2 (en) 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Crystalline forms of carbazitaxel and process for preparation thereof
JP6025861B2 (ja) 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
CA2864029A1 (en) * 2012-02-10 2013-08-15 Aventis Pharma S.A. New pediatric uses of cabazitaxel
CN104220431A (zh) 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
CN104583189A (zh) 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
TWI599373B (zh) 2012-08-15 2017-09-21 永信藥品工業股份有限公司 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之穩定醫藥調配物
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865675A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
WO2016113752A2 (en) 2015-01-12 2016-07-21 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
US10555926B2 (en) * 2015-02-17 2020-02-11 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
MX2019006206A (es) 2016-11-29 2019-08-14 Censa Pharmaceuticals Inc Polimorfos de sepiapterina y sales de los mismos.
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
CA3073957A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
RS65874B1 (sr) 2018-05-30 2024-09-30 Ptc Therapeutics Mp Inc Primena sepiapterina bez hrane za upotrebu u postupku za povećanje izloženosti plazme sepiapterinu
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
ATE256117T1 (de) * 1999-05-17 2003-12-15 Bristol Myers Squibb Co Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen
TWI333856B (en) * 2001-11-29 2010-12-01 Daiichi Seiyaku Co Crystals of taxane and process for their production

Also Published As

Publication number Publication date
RS20060189A (en) 2008-06-05
MA28045A1 (fr) 2006-07-03
BRPI0414492A8 (pt) 2019-01-15
AR045667A1 (es) 2005-11-02
BRPI0414492A (pt) 2006-11-14
KR20060072147A (ko) 2006-06-27
RU2342373C2 (ru) 2008-12-27
RU2006113122A (ru) 2006-08-27
FR13C0037I2 (fr) 2015-11-20
RS54614B1 (en) 2016-08-31
MEP11708A (en) 2010-06-10
JP5010279B2 (ja) 2012-08-29
DK1667986T3 (da) 2013-05-06
TW200524891A (en) 2005-08-01
FR2859996B1 (fr) 2006-02-03
HK1093340A1 (en) 2007-03-02
ZA200602255B (en) 2007-07-25
ES2403149T4 (es) 2013-06-24
EP1667986A1 (fr) 2006-06-14
IL174240A0 (en) 2006-08-01
KR101123588B1 (ko) 2012-03-22
CY2013016I2 (el) 2018-01-10
NO20061714L (no) 2006-04-19
WO2005028462A1 (fr) 2005-03-31
US20050065138A1 (en) 2005-03-24
UA87115C2 (ru) 2009-06-25
TWI382022B (zh) 2013-01-11
CY2013016I1 (el) 2018-01-10
BE2013C036I2 (me) 2023-12-14
LU92172I9 (me) 2019-01-03
EP1667986B1 (fr) 2013-01-16
CA2539309A1 (fr) 2005-03-31
AU2004274212A1 (en) 2005-03-31
CN100429207C (zh) 2008-10-29
MXPA06002639A (es) 2006-06-05
NO335997B1 (no) 2015-04-20
CY1114575T1 (el) 2016-10-05
HUS1300025I1 (hu) 2016-08-29
NO2015013I1 (no) 2015-05-04
FR13C0037I1 (fr) 2013-09-08
AU2004274212B2 (en) 2010-03-04
PL1667986T3 (pl) 2013-06-28
PT1667986E (pt) 2013-04-24
US7241907B2 (en) 2007-07-10
CR8292A (es) 2008-10-15
TNSN06086A1 (en) 2007-10-03
NO2015013I2 (no) 2015-04-22
MY136668A (en) 2008-11-28
CN1849311A (zh) 2006-10-18
PE20050870A1 (es) 2005-11-21
ES2403149T3 (es) 2013-05-14
HRP20130322T1 (en) 2013-07-31
PA8612401A1 (es) 2005-08-04
LU92172I2 (fr) 2013-05-21
FR2859996A1 (fr) 2005-03-25
SI1667986T1 (sl) 2013-05-31
JP2007505866A (ja) 2007-03-15
IL174240A (en) 2010-12-30
NZ545835A (en) 2009-10-30

Similar Documents

Publication Publication Date Title
ME00054B (me) Acetonski solvati dimetoksi docetaksela i postupci za njihovo dobijanje
DK1663185T3 (da) Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab
BR9908004A (pt) Composto, composição e método para prevençãoou supressão de uma infecção viral
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
NO20045429L (no) Kombinasjon av organiske forbindelser
NO20083958L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
BR0116922A (pt) Processo para a fabricação de uma composição aquosa parenteral isenta de sulfóxido de dimetila com baixa toxicidade; e composição aquosa parenteral de baixa toxicidade isenta de sulfóxido de dimetila
MY148297A (en) Process for modifying drug crystal formation
NO20022201L (no) Lösninger inneholdende Epinastin
DE602004027251D1 (de) Herstellung von 1,3-diphenylprop-2-en-1-onderivaten
HUP0500478A2 (hu) Taxánszármazékokat tartalmazó tumorellenes készítmények
ES2186550B2 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
BR0311752A (pt) Métodos de controle de pelo menos uma praga invertebrada, composição e compostos das fórmulas ii e id
CY1113176T1 (el) Παρασκευη ταξανων απο 9-διυδρο-13-ακετυλοβακκατινη iii
NO20045496L (no) Anvendelse av nefopam for behandling av kvalme eller emesis
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
DE50106211D1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
DK1525188T3 (da) Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem
ES2076838T3 (es) Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.
MX2022003868A (es) Composiciones para el cuidado bucal que comprenden un cannabinoide.
BR0104352A (pt) Taxanos substituìdos por c10 carbamoilóxi como agentes antitumorais
DK1638948T3 (da) Diphenylurinstofderivater og deres anvendelse som chloridkanalblokkere